Clinical Trial Update: A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) [Phase 1]

View source ↗

Summary

Phase Ib/Phase 1 clinical trial evaluating azacitidine, venetoclax, and allogeneic NK cells in acute myeloid leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Allogeneic NK cells (allogeneic natural killer cells)
• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING